Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic Nephropathy Pipeline Drugs Market Overview
Diabetic Nephropathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.
Key Targets in the Diabetic Nephropathy Pipeline Drugs Market
In the Diabetic Nephropathy pipeline drugs market, the key targets are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2. Cannabinoid Receptor 1 has the highest pipeline products.
Diabetic Nephropathy Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Diabetic Nephropathy Pipeline Market
The key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist. Cannabinoid Receptor 1 Antagonist has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Diabetic Nephropathy Pipeline Market
The key RoA in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic. Oral has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Diabetic Nephropathy Pipeline Drugs Market
In the Diabetic Nephropathy pipeline drugs market, the key molecule types are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein. Small molecule has the highest pipeline products.
Diabetic Nephropathy Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Diabetic Nephropathy Pipeline Market
The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc. AstraZeneca Plc has the highest number of pipeline products.
Diabetic Nephropathy Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2 |
Key MoA | Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist |
Key RoA | Oral, Intravenous, Subcutaneous, Parenteral, Topical, Intraarterial, Intravitreal, Nasogastric, and Ophthalmic |
Key molecule types | Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Antisense Oligonucleotide, Biologic, Antisense RNAi Oligonucleotide, Peptide, Recombinant Peptide, and Recombinant Protein |
Key companies | AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AIBIOS Co Ltd
Akebia Therapeutics Inc
Algomedix Inc
Anagenics Ltd
APT Therapeutics Inc
AptaBio Therapeutics Inc
Araim Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Betagenon AB
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Caladrius Biosciences Inc
CCRP Therapeutics GmbH
Certa Therapeutics Pty Ltd
ChemoCentryx Inc
Chinook Therapeutics Inc
Corbus Pharmaceuticals Inc
CSL Ltd
Curacle Co Ltd
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
Frontbio Co Ltd
Future Medicine Co Ltd
GenKyoTex SA
Gilead Sciences Inc
Glycadia Inc
Gmax Biopharm LLC
GNI Group Ltd
Goldfinch Bio Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Nanxin Pharmaceutical Co Ltd
Hua Medicine Shanghai Ltd
Inovio Pharmaceuticals Inc
InSilico Medicine
Inversago Pharma Inc
Johnson & Johnson
Landos Biopharma Inc
MediPost Co Ltd
Merck & Co Inc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
Nanjing Aimeifei Biomedical Technology Co Ltd
Novartis AG
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
Orbsen Therapeutics Ltd
PhytoHealth Corp
Poxel SA
Praetego Inc
ProKidney LLC
RAGE Biotech Pty Ltd
Reata Pharmaceuticals Inc
Rebus Holdings Inc
Scohia Pharma Inc
Secarna Pharmaceuticals GmbH & Co KG
Serodus ASA
Shanghai Alebund Pharmaceuticals Ltd
Shanghai Pharmaceutical Group Co Ltd
siRNAgen Therapeutics Corp
Slate Bio Inc
Sulfateq BV
Unicyte AG
Vidasym Inc
Wuhan Hamilton Bio-technology Co Ltd
Wuhan LL Science and Technology Development Co Ltd
XORTX Therapeutics Inc
ZyVersa Therapeutics Inc
Table of Contents
Frequently asked questions
-
What are the key targets in the Diabetic Nephropathy pipeline drugs market?
The key targets in the Diabetic Nephropathy pipeline drugs market are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2.
-
What are the types of key MoA in the Diabetic Nephropathy pipeline market?
The types of key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist.
-
What are the types of key RoA in the Diabetic Nephropathy pipeline market?
The key routes of administration in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic.
-
What are the key molecule types in the Diabetic Nephropathy pipeline market?
The key molecule types in the Diabetic Nephropathy pipeline market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein.
-
What are the key companies in the Diabetic Nephropathy pipeline market?
The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reports

